| 000 | 01901 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516103038.0 | ||
| 264 | 0 | _c20130131 | |
| 008 | 201301s 0 0 eng d | ||
| 022 | _a1879-2472 | ||
| 024 | 7 |
_a10.1016/j.thromres.2012.06.024 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aIsordia-Salas, Irma | |
| 245 | 0 | 0 |
_aThe impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population. _h[electronic resource] |
| 260 |
_bThrombosis research _cSep 2012 |
||
| 300 |
_ae67-72 p. _bdigital |
||
| 500 | _aPublication Type: Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 |
_aAcute Coronary Syndrome _xdrug therapy |
| 650 | 0 | 4 |
_aAspirin _xtherapeutic use |
| 650 | 0 | 4 | _aClopidogrel |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP3A _xgenetics |
| 650 | 0 | 4 |
_aDrug Resistance _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGenetic Predisposition to Disease _xepidemiology |
| 650 | 0 | 4 |
_aGenetic Variation _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMexico _xepidemiology |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aPlatelet Glycoprotein GPIIb-IIIa Complex _xgenetics |
| 650 | 0 | 4 |
_aPolymorphism, Single Nucleotide _xgenetics |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 |
_aReceptors, Purinergic P2Y12 _xgenetics |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aThrombosis _xepidemiology |
| 650 | 0 | 4 |
_aTiclopidine _xanalogs & derivatives |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aOlalde-Román, Marcos Jaciel | |
| 700 | 1 | _aSantiago-Germán, David | |
| 700 | 1 | _ade la Peña, Norma Corona | |
| 700 | 1 | _aValencia-Sánchez, Jesús Salvador | |
| 773 | 0 |
_tThrombosis research _gvol. 130 _gno. 3 _gp. e67-72 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.thromres.2012.06.024 _zAvailable from publisher's website |
| 999 |
_c21963544 _d21963544 |
||